The Oxford COVID-19 vaccine developed by the scientist from Jenner’s institute and Oxford vaccine group at University of Oxford have been proven to offer up to 70.4% protection against COVID-19 according to an interim analysis. The Oxford COVID-19 was made from a weakened adenovirus that usually cause common cold in chimpanzee and it has been proven to show strong immunity against COVID-19 in both teens and older adults.
According to an interim data the Oxford COVID-19 shows up to 70.4% protection against COVID-19 in a combined data after getting two doses of the vaccine. The data from the first dose of the vaccine shows 90% efficacy while the second dose presented 62% protection. The Director of Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, Professor Andrew Pollard said “These findings shows that we have an effective vaccine that will save many lives. Excitingly , we have found that one of our dosing regimen is used, more people could be vaccinated with planned vaccine supply”. He also thanked the volunteer that were recruited for the vaccine trial and the intelligent and highly talented researcher teams around the world that made the vaccine trial successful.
“This is a great day for the University of Oxford and for Universities everywhere. Pushing at the frontier of knowledge with partners across the globe and putting our extra ordinary brain power in service to society is what we do best” Said University of Oxford vice-chancellor Professor Louise Richardson.
The final clinical trial for the Oxford COVID-19 vaccine is currently going on in the United kingdom, Brazil, South Africa, United States, Japan, India and Kenya with the aim to determine how effective and safe the vaccine will be in the large population of participants.